skip to content

Personalising diabetes care: a holistic approach to cardiometabolic health

Woman in a striped tank top sitting on a climbing gym floor, tying shoes, looks up at a colorful climbing wall with focus and determination.

Every day, millions of people wake up to the reality of living with diabetes, a condition that now affects nearly 600 million adults worldwide.1 It’s not just a vast statistic, it’s a growing challenge that touches families, communities, and economies, with incidence rising fastest in low- and middle-income countries. Behind these growing numbers are people impacted by not only the ongoing daily management of diabetes, but its complications as well such blindness, kidney failure, strokes, and even amputations.2

There are two key types of diabetes - Type 1 , and Type 2, with Type 2 representing approximately 90% of cases. Both types are characterised by a dysfunction of the body’s insulin system where the body is not able to produce enough insulin, cannot use it well enough, or both. The shared outcome of this system failure is a high level of glucose in the bloodstream, known as hyperglycaemia. If glucose levels become very high, or stay high for a long time, this can lead to serious health impacts and widespread effects on other organs and systems, creating a cascade of additional health risks and comorbidities.3-5

One of the most serious health risks of diabetes is cardiovascular disease. People living with diabetes face a 2-4 times higher risk of hypertension, heart failure, stroke, and coronary artery disease than those without it. Prolonged high blood glucose silently damages blood vessels and nerves, making cardiovascular complications more likely, more frequent and more severe over time.6-8

Photo of Dr Manu Chakravarthy

Diabetes and obesity are not isolated conditions. They’re deeply interconnected, multifaceted diseases shaped by biology, behaviour, and environment. To truly change outcomes, we must move beyond symptom management and deliver integrated solutions that reflect the complexity of people’s real lives.

Dr Manu Chakravarthy

SVP and Global Head of Cardiovascular, Renal and Metabolism (CVRM) Product Development

The critical link between diabetes and obesity

Adding to the risks of living with diabetes is the critical, interlinked factor of obesity. Excess body fat is a major risk factor for Type 2 Diabetes (T2D) because it contributes significantly to insulin resistance and dysfunction of the cells that produce insulin. Consequently, people living with obesity are seven times more likely to develop T2D than those with a normal body mass index. This link also provides opportunities for new treatment approaches as weight loss in people with obesity and T2D has been shown to put their diabetes into remission.

In Type 1 Diabetes (T1D), a challenging side effect can be weight gain, often because insulin itself is an anabolic hormone that promotes fat storage. Weight gain increases insulin resistance, which then exacerbates issues with keeping glucose levels within a healthy range (known as glycaemic control). The consequence is a reliance on even higher doses of insulin, which can perpetuate a vicious cycle of further weight gain and increase the risk of cardiovascular comorbidities. T1D remains a disease with significant unmet needs, with approximately 70% of patients on insulin struggling with glucose control as well as significant burden of organ damage leading to Chronic Kidney Disease.

Regardless of the type of diabetes, excess weight is a concern for the entire diabetes community as it may hinder the ability to engage in regular physical activity or maintain a balanced diet, both of which are crucial for improving glycaemic control.10

While the disruption of the body's insulin system is the core challenge in both types, effective management fundamentally diverges, demanding precision and personalisation in care.11 For people living with T1D, lifelong daily insulin therapy is mandatory, demanding meticulous, and accurate dosing. Daily life is dominated with constant calculations, carbohydrate counting and awareness for low blood glucose levels (hypoglycaemia). Being in this constant state of alert results in a very heavy emotional burden and distress all day long,12 with little respite or opportunity for spontaneity for simple activities like taking a walk after lunch. "Every single aspect of your life sometimes revolves around the decisions you make about what you do with your blood sugar," says Cajsa Lindberg, living with T1D since her early childhood.

In contrast, T2D management initially focuses on intensive lifestyle modification, aggressive weight control, and systematically addressing comorbidities like hypertension. It is important that T2D is understood to be a chronic, lifelong disease (that can also include remission) requiring long-term strategies centred on reducing the most serious risk, which is cardiovascular events. This underscores the complexity of a global challenge; it's not one disease, but manifold battles, each requiring specialised and continuous support, including awareness of stigma and its mental health toll.13-14

Beyond current treatment approaches, people with diabetes urgently require more convenient and predictive ways to manage their blood glucose. Diabetes is a highly complex and unpredictable disease as blood glucose levels are influenced by a large number of factors, and people living with the chronic condition, especially those with T1D, can face up to 200 decisions every day.15 Some of the factors that influence glucose levels are outside of an individual’s direct control, such as other illnesses or medications, outside temperature, sleep, stress and allergies for example, further complicating daily decision-making.16-17

Continuous Glucose Monitoring (CGM) is transforming this landscape by providing a fuller picture of glucose levels than traditional monitoring methods. Real-time CGM solutions offer continuous insights into glucose values and trends, helping people with diabetes move toward a more comprehensive approach to care. Critically, artificial intelligence (AI)-enabled algorithms enhance the predictive functionalities of these solutions, which puts the power of prediction into the hands of people living with diabetes. This shift enables them to proactively intervene when their glucose course requires attention before a complication occurs, thereby moving diabetes management from a reactive to a proactive approach. “Enhancing the technology we currently possess is already mind-blowing. It makes diabetes management easier and brings more moments of happiness – a gift for anyone living with diabetes." says Hanna Boëthius, who was first diagnosed with T1D in 1985. Furthermore, these predictive capabilities are designed to address the intense concerns of people with diabetes and their caregivers regarding night-time hypoglycemia, specifically aiming to lower the risk of low night-time glucose levels. Recent evidence confirms the use of AI-enabled CGM significantly reduces the likelihood of hypoglycaemia at night, easing stress and the constant fear of hypoglycaemia.18-20

This focus on prediction extends to the biggest threat, cardiovascular risk. Since cardiovascular disease is the leading cause of death in this population, simply managing glucose is not enough.6 Recent real-world data from over 115,000 people with diabetes highlights the value of screening for the biomarker natriuretic peptide, which can predict heart failure risk, including people with Type 1 diabetes, underscoring the importance of integrating advanced cardiovascular screening into routine diabetes care.21

As outlined, the sheer scope and complexity of the diabetes challenge, from the critical obesity link and the distinct management needs to the persistent threat of cardiovascular risk, demand a holistic, future-focused response. Roche is redefining cardiometabolic care through a patient-first model that spans diagnosis, treatment, and monitoring, specifically by combining digital tools and biomarkers for predictive insights with AI-powered platforms for continuous monitoring and disease forecasting. This unified approach enables us to focus on providing the right care, at the right time fundamentally working to support people across every stage of their journey and driving meaningful progress in cardiometabolic health worldwide.

References

  1. Diabetes Atlas 589 people worldwide have diabetes million. (n.d.). Available at: https://diabetesatlas.org/media/uploads/sites/3/2025/10/IDF_Diabetes_Atlas_11th_Edition_2025_WEB.pdf

  2. World Health Organization (2024). Diabetes. [online] World Health Organization. Available at: https://www.who.int/news-room/fact-sheets/detail/diabetes.

  3. Nichols, H. (2023). Types 1 and 2 diabetes: Similarities and differences. [online] www.medicalnewstoday.com. Available at: https://www.medicalnewstoday.com/articles/7504.

  4. Breakthrough T1D (2024). Causes of type 1 diabetes | Breakthrough T1D UK. [online] Breakthrough T1D UK. Available at: https://breakthrought1d.org.uk/knowledge-support/about-type-1-diabetes/causes-of-type-1-diabetes/.

  5. Cerf, M.E. (2013). Beta Cell Dysfunction and Insulin Resistance. Frontiers in Endocrinology, 4(37). Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC3608918/

  6. academic.oup.com. (n.d.). Validate User. [online] Available at: https://academic.oup.com/eurjpc/article/26/2_suppl/25/5925419

  7. Centers for Disease Control and Prevention (CDC) (2024). Your Heart and Diabetes. [online] Diabetes. Available at: https://www.cdc.gov/diabetes/diabetes-complications/diabetes-and-your-heart.html.

  8. American Heart Association (2024). Cardiovascular Disease and Diabetes. [online] www.heart.org. Available at: https://www.heart.org/en/health-topics/diabetes/diabetes-complications-and-risks/cardiovascular-disease--diabetes.

  9. Davison, L. (n.d.). Diabetes and Obesity: A Growing Public Health Challenge Corresponding Author*. [online] doi: https://www.iomcworld.com/open-access/diabetes-and-obesity-a-growing-public-health-challenge.pdf

  10. Mottalib, A., Kasetty, M., Mar, J.Y., Elseaidy, T., Ashrafzadeh, S. and Hamdy, O. (2017). Weight Management in Patients with Type 1 Diabetes and Obesity. Current Diabetes Reports, 17(10). doi: https://pmc.ncbi.nlm.nih.gov/articles/PMC5569154/

  11. American Diabetes Association Professional Practice Committee (2024). Obesity and weight management for the prevention and treatment of type 2 diabetes: Standards of care in diabetes–2025. Diabetes Care, [online] 48(Supplement_1), pp.S167–S180. doi: https://diabetesjournals.org/care/article/48/Supplement_1/S167/157555/8-Obesity-and-Weight-Management-for-the-Prevention

  12. Diabetes UK (2024). Chapter 3 - Diabetes distress. [online] Diabetes UK. Available at: https://www.diabetes.org.uk/for-professionals/improving-care/good-practice/psychological-care/emotional-health-professionals-guide/chapter-3-diabetes-distress

  13. American Diabetes Association Professional Practice Committee. Standards of Care in Diabetes—2024. Diabetes Care. 2024;47(Supplement 1):S1-S314. Available at: https://diabetesjournals.org/care/issue/47/Supplement_1

  14. Diabetes UK. (2025). 86% of people with type 1 and 75% of people with type 2 experience judgement for their condition. [online] Available at: https://www.diabetes.org.uk/about-us/news-and-views/86-people-type-1-and-75-people-type-2-experience-judgement-their-condition

  15. Diabetes UK. (n.d.). Easing the burden for people with diabetes. [online] Available at: https://www.diabetes.org.uk/about-us/news-and-views/easing-burden-people-diabetes.

  16. Makingdiabeteseasier.com. (2025). How does the environment affect your blood glucose levels? [online] Available at: https://www.makingdiabeteseasier.com/uk/managing-diabetes/blood-glucose-levels-0/environment-and-blood-glucose-effects

  17. Sacks, E. (2023). Meds That Can Spike Your Blood Sugar. [online] WebMD. Available at: https://www.webmd.com/diabetes/medicines-blood-sugar-spike

  18. Klupa, T., Czupryniak, L., Dzida, G., Fichna, P., Jarosz-Chobot, P., Gumprecht, J., Mysliwiec, M., Szadkowska, A., Bomba-Opon, D., Czajkowski, K., Malecki, M.T. and Zozulinska-Ziolkiewicz, D.A. (2023). Expanding the Role of Continuous Glucose Monitoring in Modern Diabetes Care Beyond Type 1 Disease. Diabetes Therapy, 14(8). doi: https://pubmed.ncbi.nlm.nih.gov/37322319/

  19. Ólafsdóttir, A.F., Polonsky, W., Bolinder, J., Hirsch, I.B., Dahlqvist, S., Wedel, H., Nyström, T., Wijkman, M., Schwarcz, E., Hellman, J., Heise, T. and Lind, M. (2018). A Randomized Clinical Trial of the Effect of Continuous Glucose Monitoring on Nocturnal Hypoglycemia, Daytime Hypoglycemia, Glycemic Variability, and Hypoglycemia Confidence in Persons with Type 1 Diabetes Treated with Multiple Daily Insulin Injections (GOLD-3). Diabetes Technology & Therapeutics, 20(4), pp.274–284. doi: https://doi.org/10.1089/dia.2017.0363.

  20. Ehrmann D, et al. J Diabetes Sci Technol 2024;18(5):1027–34; 3. Hussain S, et al. Diabetes Technol Ther 2025: 10.1089/dia.2025.0293.

  21. Pop-Busui, R., Repetto, E., Baron, J., Schumacher, D., Vaduganathan, M. and Pandey, A. (2025). Screening Natriuretic Peptide Levels Predicts Heart Failure and Death in Individuals With Type 1 and Type 2 Diabetes Without Known Heart Failure. Diabetes care, [online] p.dc251260. doi: https://pubmed.ncbi.nlm.nih.gov/41166576/

More stories of

See all stories